New Year Outlook

Three UK medtech companies’ views on how their businesses will be influenced by external factors in the coming year.

The latest insights into work conducted to support the implementation of the IVDR show that much has been achieved already. Ongoing projects remain, however, including those that are continuous. 2024 promises to be a busy year. 

Medtech Insight and HBW Insight reached out to industry stakeholders for feedback on new climate-related disclosure requirements and growing environmental, social and governance (ESG) pressures on businesses.

Views from medtech industry leaders and investors on the most significant uncertainties and opportunities facing the sector in 2024. 

Views from industry experts and the US FDA on priorities and regulatory topics to watch in 2024. 

Ongoing threats to the availability of medical devices, obstacles to innovation, delayed structures and documents.... The medtech sector has plenty of reason to call for change in 2024.

Compliance with greenhouse gas reduction targets is not optional for medtech businesses who, besides the bigger picture, have their own sustainability to think of. Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation. In the EU, the MDR is also having an effect on innovation strategies.